ArticleHuman pathology2025
Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing.
Article in Human pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of neoadjuvant chemotherapy in micropapillary urothelial carcinoma: a multi-institutional analysis from the Korean Bladder Cancer Research Group.International urology and nephrology · 2026Article
- Redefining breast cancer: therapeutic opportunities in HER2-low and emerging molecular subtypes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Micropapillary urothelial carcinoma (MPUC) is an aggressive neoplasm with distinct histology. We examined the molecular profile of MPUC and its relationship to patients' clinicopathologic features in 99 patients who underwent next-generation sequencing from 2010 to 2020 at a single institution. The patients included 77 men and 22 women with a mean age of 68 years (range, 24-91 years). Next-generation sequencing was performed on primary (n = 74) and metastatic (n = 25) tumor specimens. Somatic gene mutations were detected in 98 tumors, and the most common mutations were TP53 (n = 71), TERT (n = 49), ARID1A (n = 28), ERBB2 (n = 24), and RB1 (n = 22). Copy number variations were detected in 22 tumors, including ERBB2 (n = 8), CDK12 (n = 3), CCND1 (n = 3), and other genes (n = 8). No gene fusions or microsatellite instability was detected. Human epidermal growth factor receptor 2 (HER2) overexpression was detected more frequently in MPUCs with ERBB2 amplifications than those with ERBB2 mutations. Individual gene mutations did not significantly affect the overall survival, but patients with ERBB2 amplifications had a significantly shorter overall survival than those with ERBB2 mutations (p = 0.043). MPUC demonstrated distinct gene alterations in oncogenes and tumor suppressor genes that may be involved in MPUC's oncogenesis. ERBB2 gene amplifications were associated with HER2 overexpression in MPUC, which may contribute to MPUC's aggressive behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.